Inclisiran

• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown
  2022-502779-40-99 Phase III 20 countries Novartis Pharma AG
• Study to evaluate efficacy and safety of inclisiran in children aged 2 to under 12 years of age with homozygous familial hypercholesterolemi… Recruiting
  2024-514595-41-00 Phase III 6 countries Novartis Pharma AG
• Evaluation of efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes Recruiting
  2025-521670-34-00 Phase III 5 countries Novartis Pharma AG
• Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD Recruiting
  2024-516356-18-00 Phase III 5 countries Novartis Pharma AG
• Comparison of inclisiran or alirocumab to standard therapy in pediatric heterozygous familial hypercholesterolemia (HeFH) – the head-to-head… Recruiting
  2024-514523-42-00 Phase III 1 country Medical University Of Lodz
• Study to evaluate efficacy and safety of inclisiran in children aged 6 to under 12 years of age with heterozygous familial hypercholesterole… Recruiting
  2024-514594-21-00 Phase III 12 countries Novartis Pharma AG
• The relationship of cholesterol-lowering drugs with steroid HORMONEs, bile acids, muscle morphology, vitamin D, the immune system and relate… Recruiting
  2024-516967-10-00 Phase IV 1 country Medical University Of Vienna
• Long-term safety and tolerability of inclisiran in participants with heterozygous familial hypercholesterolaemia or homozygous familial hype… Recruiting
  2023-507278-41-00 Phase III 12 countries Novartis Pharma AG
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended
  2022-502779-40-00 Phase III 20 countries Novartis Pharma AG
• Semmelweis Lipid Center for High-risk Patients Ended
  2024-519058-35-00 Phase IV 1 country Semmelweis University
• Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic P… Ended
  2024-511126-31-00 Phase III 6 countries Novartis Pharma AG
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended
  2024-510735-21-00 Phase III 24 countries Novartis Pharma AG
• Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of … Ended
  2024-511263-28-00 Phase IV 8 countries Novartis Pharma AG

Showing 1–13 of 13 trials